Filing Flows › Comparisons › AKTS vs RNA
Aktis Oncology vs Atrium Therapeutics: AKTS and RNA compared
Aktis Oncology is the larger company: $3.4M of revenue in its latest quarter (Q2 2026) against $3.0M for Atrium Therapeutics (Q2 2026). Aktis Oncology is growing faster (+111% against -22% a year earlier). Atrium Therapeutics is more profitable, with an operating margin of -752.9% against -854.0%.
Where the money goes: AKTS and RNA
Aktis Oncology (AKTS) · Q2 2026
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.
Atrium Therapeutics (RNA) · Q2 2026
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%, net loss $20.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
| Aktis Oncology (AKTS) | Atrium Therapeutics (RNA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $3.4M | $3.0M |
| Revenue growth, Y/Y | +111% | -22% |
| Operating margin | -854.0% | -752.9% |
| Net earnings | −$24.1M | −$20.2M |
| Net margin | -713.5% | -672.0% |
| Operating cash flow | −$20.6M | −$3.9M |
Questions
Which is bigger, Aktis Oncology or Atrium Therapeutics?
Aktis Oncology is the larger company: $3.4M of revenue in its latest quarter (Q2 2026) against $3.0M for Atrium Therapeutics (Q2 2026).
Is Aktis Oncology or Atrium Therapeutics growing faster?
Aktis Oncology is growing faster (+111% against -22% a year earlier).
Which is more profitable, Aktis Oncology or Atrium Therapeutics?
Atrium Therapeutics is more profitable, with an operating margin of -752.9% against -854.0%.
More: Aktis Oncology earnings · how Aktis Oncology makes money · Atrium Therapeutics earnings · how Atrium Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.